Scarica l'app Stockscreener
1.17
1.74%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.15
Aprire:
$1.17
Volume 24 ore:
2.32M
Relative Volume:
0.46
Capitalizzazione di mercato:
$241.80M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.5519
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+14.71%
1M Prestazione:
+11.43%
6M Prestazione:
-46.58%
1 anno Prestazione:
-50.42%
Intervallo 1D:
$1.15
$1.215
Intervallo di 1 settimana:
$0.949
$1.215
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.17 | 241.80M | 116.33M | -209.25M | -135.49M | -2.12 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.99 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.18 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.25 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.01 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada
ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World
Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance
Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa
Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia
ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa
Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com
Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks
Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times
Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World
Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World
Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World
BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
D. E. Shaw & Co. Inc. Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Northern Trust Corp Buys 65,662 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics discovers new ATP citrate lyase inhibitors - BioWorld MedTech
Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire
Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com
Esperion to Present Latest Cardiovascular Drug Developments at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Brokerages - Defense World
Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com
Raymond James Financial Inc. Invests $98,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com
Esperion reaches settlement agreement with Micro Labs - TipRanks
Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq
Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent Dispute | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com
Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq
Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - Stock Titan
Cantor Fitzgerald Has Negative View of ESPR FY2025 Earnings - Defense World
Needham & Company LLC Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $4.00 - Defense World
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Esperion Therapeutics Inc Azioni (ESPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Jun 17 '25 |
Sale |
1.11 |
30,474 |
33,796 |
1,541,488 |
| Halladay Benjamin | Chief Financial Officer |
Jun 17 '25 |
Sale |
1.15 |
7,229 |
8,328 |
474,473 |
0.54%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):